Gen3009 is a bispecific IgG1 antibody targeting two non-overlapping epitopes on CD37 (biparatopic) with an E430G hexamerization-enhancing mutation. It exhibits significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, with the potential to treat human B-cell malignancies. MW: 145.37 KD.